All AbMole products are for research use only, cannot be used for human consumption.
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.
CAS Number | 2136633-23-1 |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
[3] Hélène Kaplon, et al. MAbs. Antibodies to watch in 2022
Related Drug-Linker Conjugates for ADC Products |
---|
MC-SN38
MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). |
DM4-SMCC
DM4-SMCC is a agent-linker conjugate for ADC with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker. |
Lys-SMCC-DM1
Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. |
Doxorubicin-SMCC
Doxorubicin-SMCC is a agent-linker conjugate for ADC. |
Mal-PEG4-VC-PAB-DMEA-PNU-159682
Mal-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.